Kura Oncology, Inc. - Common Stock (KURA)
6.1500
-0.3700 (-5.67%)
NASDAQ · Last Trade: Apr 3rd, 1:27 PM EDT
Via Benzinga · April 1, 2025

Via Stocktwits · February 12, 2025

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.
Via Benzinga · February 6, 2025

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · February 5, 2025

These two healthcare growth stocks could have a lot more room to run.
Via The Motley Fool · May 8, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via Benzinga · February 27, 2024

Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset.
Via Investor's Business Daily · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · October 14, 2024

KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.
Via InvestorPlace · July 17, 2024

KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 2, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via Talk Markets · February 22, 2024

The company just released promising results for its acute myeloid leukemia treatment.
Via Investor's Business Daily · January 30, 2024

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Via Benzinga · January 30, 2024

Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.
Via Benzinga · January 30, 2024

U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday.
Via Benzinga · January 30, 2024

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&P 500 also rose, gaining, 0.29% to 4,878.52.
Via Benzinga · January 24, 2024